- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
Interleukins
Interleukins製品
- All (147)
- Interleukins阻害剤 (58)
- Interleukins抗体(78)
- Interleukins活性剤(4)
- Interleukins拮抗剤(1)
- Interleukins作動薬(1)
- Interleukinsモジュレータ(4)
- 新製品
| 製品コード | 製品名称 | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|---|
| S7455 | Resatorvid (TAK-242) | Resatorvid (TAK-242, CLI-095) is a small-molecule-specific inhibitor of Toll-like receptor (TLR) 4 signaling, blocking LPS-induced production of NO, TNF-α and IL-6 in macrophages with IC50 of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy. | ||
| S1189 | Aprepitant | Aprepitant is a potent and selective neurokinin-1 receptor antagonist with IC50 of 0.1 nM. Aprepitant reduces levels of pro-inflammatory cytokines including G-CSF, IL-6, IL-8 and TNFα. Aprepitant inhibits HIV infection of human macrophages. |
|
|
| S1709 | Estradiol | Estradiol (17β-estradiol, β-Estradiol, E2, 17β-Oestradiol) is a human sex hormone and steroid, and the primary female sex hormone. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway. | ||
| S8966 | T-5224 | T-5224 is a selective inhibitor of transcription factor c-Fos/activator protein (AP)-1 with anti-inflammatory effects. T-5224 specifically inhibits the DNA binding activity of c-Fos/c-Jun and the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription. | ||
| S8133 | Resiquimod (R-848) | Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2. | ||
| S6414 | Apilimod | Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod (STA-5326) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod (STA-5326) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM. | ||
| S7259 | FLLL32 | FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells. |
|
|
| S8301 | Ossirene (AS101) | Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta converting enzyme. | ||
| S4267 | Diacerein | Diacerein is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis. |
|
|
| S1733 | Methylprednisolone | Methylprednisolone (NSC-19987,U 7532) is a synthetic glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation. Methylprednisolone activates ACE2 and reduces IL-6 levels, thus improves severe or critical COVID-19. Methylprednisolone markedly reduces autophagy and apoptosis. |
|
|
| S9727 | Ac-YVAD-cmk | Ac-YVAD-cmk (Caspase-1 Inhibitor II) is a selective IL-1β converting enzyme (ICE) inhibitor with neuroprotective and anti-inflammatory effects, effectively suppresses the expression of IL-1β and IL-18. | ||
| A2025 | Secukinumab (anti-IL-17A) | Secukinumab (anti-IL-17A) (Cosentyx, AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa. | ||
| S8261 | GSK583 | GSK583 is a highly potent and selective inhibitor of RIP2 kinase with IC50 of 5 nM. GSK583 also inhibits both TNF-α and IL-6 production with IC50 of ~200 nM in explant cultures. | ||
| S0785 | Apilimod mesylate | Apilimod mesylate is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod mesylate (STA-5326 mesylate) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod mesylate (STA-5326 mesylate) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM. | ||
| S0787 | 3-Deazaadenosine hydrochloride | 3-Deazaadenosine HCl (3-DZA, c3Ado) is a potent inhibitor of S-adenosylhomocysteine hydrolase with Ki of 3.9 µM. 3-Deazaadenosine HCl inhibits bacterial lipopolysaccharide-induced transcription of TNF-α and IL-1β. 3-Deazaadenosine HCl inhibits the transcriptional activity of NF-κB, prevents FCS-induced Ras carboxyl methylation and reduces FCS-induced ERK1/2 and Akt phosphorylation. 3-Deazaadenosine HCl has anti-inflammatory, anti-proliferative and anti-HIV activities. | ||
| S3292 | Falcarindiol | Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules. | ||
| S9668 | PKR-IN-C16 | PKR-IN-C16 (C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component. | ||
| S8879 | Deucravacitinib (BMS-986165) | Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases. | ||
| S2979 | CU-T12-9 | CU-T12-9 is a specific agonist of Toll-like receptor (TLR) 1/2 with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS. | ||
| S2015 | Suplatast Tosylate | Suplatast Tosylate (IPD-1151T, Suplatast Tosilate) is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM. | ||
| S6281 | Sodium Thiocyanate | Sodium Thiocyanate (NaSCN, Sodium rhodanide, Sodium sulfocyanate, Sodium rhodanate), one of the main sources of the thiocyanate anion, is used as a precursor for the synthesis of pharmaceuticals and other specialty chemicals. Sodium thiocyanate (NaSCN) reduces IL-6, whereas increases IL-10 levels. Sodium thiocyanate also reduces ROS. | ||
| S0826 | A-740003 | A-740003 is a potent, selective and competitive antagonist of P2X7 receptor with IC50 of 18 nM and 40 nM for rat and human P2X7 receptors, respectively. A-740003 potently blocks agonist-evoked IL-1β release and pore formation with IC50 of 156 nM and 92 nM in differentiated human THP-1 cells. | ||
| S6898 | RCM-1 | RCM-1 is a nontoxic inhibitor of Forkhead box M1 (FOXM1) that suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. RCM-1 decreases carcinogenesis and nuclear β-catenin. | ||
| S0771 | BRD6989 | BRD6989 is a selective inhibitor of CDK8 and CDK19. BRD6989 upregulates IL-10. BRD6989 is an analog of the natural product cortistatin A (dCA). | ||
| S0094 | SR 0987 | SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer. | ||
| S5972 | Hydrocortisone hemisuccinate | Hydrocortisone hemisuccinate (A-hydrocort, Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid with anti-inflammatory properties, is an inhibitor of proinflammatory cytokine with IC50 of 6.7 μM and 21.4 μM for Interleukin-6 (IL-6) and IL-3, respectively. | ||
| S9052 | Auraptene | Auraptene (7-geranyloxycoumarin) is a natural coumarin derived from citrus plants and possesses valuable pharmacological properties, including anticarcinogenic, anti-inflammatory, antihelicobacter, antigenotoxic, and neuroprotective effects. Auraptene inhibits matrix metalloproteinase 2 (MMP-2) as well as key inflammatory mediators, including IL-6, IL-8 and chemokine (C-C motif) ligand-5(CCL5). | ||
| S9374 | 2',5'-Dihydroxyacetophenone | 2',5'-Dihydroxyacetophenone (DHAP, 2-Acetylhydroquinone, Quinacetophenone) is a mixture of dihydroxyacetophenone isomers is used in food flavouring. 2',5'-Dihydroxyacetophenone significantly inhibits NO production via the suppression of iNOS expression. 2',5'-Dihydroxyacetophenone significantly decreases levels of the pro-inflammatory cytokines TNF-α and IL-6 by blocking the ERK1/2 and NF-κB signaling pathways. | ||
| S3871 | Muscone | Muscone (3-Methylcyclopentadecanone, Methylexaltone), a flavouring ingredient, is an organic compound that is the primary contributor to the odor of musk and also a potent anti-inflammatory agent. Muscone significantly downregulats the levels of LPS-induced inflammatory cytokines and inhibits NF-κB and NLRP3 inflammasome activation in BMDMs. Muscone remarkably decreases the levels of inflammatory cytokines (IL-1β, TNF-α and IL-6). | ||
| S6620 | Danirixin (GSK1325756) | Danirixin (GSK1325756) is a small molecule, non-peptide, high affinity (IC50 for CXCL8 (IL-8) binding = 12.5 nM), selective, and reversible CXCR2 antagonist. | ||
| A2120 | Anti-mouse IL-17A-InVivo | Anti-mouse IL-17A-InVivo monoclonal antibody (Clone:17F3) reacts with mouse IL-17A which is a 15-20 kDa cytokine expressed by Th17 cells, γδ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells. Anti-mouse IL-17A-InVivo has been shown to neutralize IL-17A in vivo. |
|
|
| S0437 | SAR-20347 | SAR-20347 is a potent inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediated IL-12 and IFN-α signaling. | ||
| S3745 | Balsalazide disodium | Balsalazide Disodium is the disodium salt form of balsalazide, an aminosalicylate and oral prodrug that is enzymatically cleaved in the colon to produce the anti-inflammatory agent mesalazine. Balsalazide Disodium suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. | ||
| S9502 | Madecassic acid | Madecassic acid (Brahmic acid), a natural triterpene first isolated from C. asiatica, has diverse anti-inflammatory and anti-diabetic effects, blocking NF-κB activation in macrophages and causing by iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 inhibition. | ||
| S0472 | EC330 | EC330 is a steroidal inhibitor of leukemia inhibitory factor (LIF, an interleukin 6 class cytokine). EC330 inhibits the LIF/LIF-R signaling and blocks the promoting effects of LIF on growth and migration of cancer cells. | ||
| S1833 | Butoconazole nitrate | Butoconazole nitrate (RS-35887) is an anti-fungal agent that inhibits PHA-stimulated release of cytokines-- IL-2, TNFα, IFN and GM-CSF from human peripheral blood lymphocytes (IC50 of 7.2 μg/mL, 14.4 μg/mL, 7.36 μg/mL and 7.6 μg/mL, respectively). | ||
| S3312 | Diethyl phosphate | Diethyl phosphate (DEP, DPF, Diethyl phosphoric acid, diethyl hydrogen phosphate), a non-specific metabolite of organophosphorus pesticides in the gut environment, significantly enriches opportunistic pathogens leading to a decrease in interleukin-6 (IL-6). |
||
| S5764 | YM 90709 | YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R). | ||
| S4842 | Balsalazide | Balsalazide (Colazal, Giazo), an aminosalicylate and oral prodrug, is enzymatically cleaved in the colon to produce the anti-inflammatory agent mesalazine. Balsalazide suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. | ||
| A2375 | Rolinsatamab (Anti-PRLR / Prolactin Receptor) | Rolinsatamab (Anti-PRLR / Prolactin Receptor) is a fully humanized bispecific monoclonal antibody that targets IL-4 and IL-13. MW: 145.5 kD. | ||
| A2822 | Depemokimab (Anti-IL-5) | Depemokimab (Anti-IL-5) is a humanized monoclonal antibody (IgG1, kappa) directed against IL-5. Depemokimab can be used for research of asthma. MW : 145.8 KD. | ||
| A2142New | Anti-mouse/rat IL-1β-InVivo | Anti-mouse/rat IL-1β-InVivo reacts with precursor and mature secreted forms of mouse and rat IL-1β a 17 kDa pro-inflammatory cytokine produced primarily by monocytes. | ||
| S3590 | Triolein | Triolein is an inhibitor of metalloproteinase-1 (MMP-1) and reduces both the expression of IL-6 and ROS generation in irradiated keratinocytes. | ||
| E0314 | JTE-607 Dihydrochloride | JTE-607 Dihydrochloride is a prodrug compound that is converted to an active form by ester hydrolysis. JTE-607 is a multiple cytokine production inhibitor that targets CPSF3 and inhibits pre-mRNA processing. JTE-607 inhibits tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50 values of 11 nM, 5.9 nM, 8.8 nM, 7.3 nM and 9.1 nM, respectively. |
||
| A2842 | Ebdarokimab (Anti-IL-12b) | Ebdarokimab (Anti-IL-12b) is a fully human monoclonal antibody (mAb) targeting Interleukin-12/Interleukin-23 (IL-12/IL-23) pathway. Ebdarokimab has the potential to treat moderate to severe plaque psoriasis. MW : 145.6 KD. | ||
| A2153New | Anti-mouse IL-2 (S4B6-1)-InVivo | Anti-mouse IL-2 (S4B6-1)-InVivo reacts with mouse IL-2, a 17 kDa cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation. | ||
| A2845 | Elsilimomab (Anti-IL-6 / IFNb2) | Elsilimomab (Anti-IL-6 / IFNb2) is an IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab has the potential to be used in research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). MW : 145.96 KD. | ||
| A2157New | Anti-mouse IL-6R-InVivo | Anti-mouse IL-6R-InVivo reacts with the mouse IL-6 receptor α chain also known as CD126. CD126 is an 80 kDa type I cytokine receptor and a member of the immunoglobulin superfamily. | ||
| S3969 | Veratric acid | Veratric acid (3,4-Dimethoxybenzoic acid), a simple benzoic acid derived from plants and fruits, has anti-oxidant, anti-inflammation, and blood pressure-lowering effects. Veratric acid reduces upregulated COX-2 expression, and levels of PGE2, IL-6 after UVB irradiation. | ||
| S9236 | α-Cyperone | α-Cyperone (alpha-cyperone), a major active compound of Cyperus rotundus, exhibits biological activities, such as antivirulence, antigenotoxic, and antibacterial activities. α-Cyperone (alpha-cyperone) is associated with the down-regulation of COX-2, IL-6, Nck-2, Cdc42 and Rac1. | ||
| A2046 | Risankizumab (anti-IL-23) | Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease. |
|
|
| A2856 | Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7) | Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7) is a gut‐selective humanized monoclonal antibody targets β7 integrins with a potential to treat inflammatory bowel disease (IBD). MW: 144.3 KD. | ||
| S0752 | AUDA | AUDA (compound 43) is a potent inhibitor of soluble epoxide hydrolase (sEH) with IC50 of 18 nM and 69 nM for the mouse sEH and human sEH, respectively. AUDA has anti-inflammatory activity that reduces the protein expression of MMP-9, IL-1β, TNF-α and TGF-β. AUDA downregulates Smad3 and p38 signaling pathways. | ||
| A2861 | Anti-CTLA-8 / IL-17a (CAT-2200) | Anti-CTLA-8 / IL-17a (CAT-2200) is a human monoclonal antibody against IL-17A (interleukin-17A) that can potently neutralize the effects of recombinant and native human IL-17A. MW: 143.72. | ||
| A2862 | Ixekizumab (Anti-CTLA-8 / IL-17a) | Ixekizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab has the potential to be used in research on plaque psoriasis. MW: 146.44 KD. | ||
| A2863 | Netakimab (Anti-CTLA-8 / IL-17a) | Netakimab (Anti-CTLA-8 / IL-17a) is a humanized monoclonal antibody against interleukin-17 (IL-17) with the potential to treat moderate to severe plaque psoriasis. MW: 145.74 KD. | ||
| A2024 | Ustekinumab (anti-IL-12/IL-23) | Ustekinumab (CNTO 1275) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody used to treat psoriasis. MW=145.6 kDa. | ||
| A2864 | Perakizumab (Anti-CTLA-8 / IL-17a) | Perakizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG1κ monoclonal antibody against interleukin-17A (IL-17A). MW: 145.8 KD. | ||
| A2134 | Anti-mouse IL-18-InVivo | Anti-mouse IL-18-InVivo (Clone:YIGIF74-1G7) monoclonal antibody reacts with mouse IL-18. IL-18 an 18 kDa pro-inflammatory cytokine is expressed by activated macrophages, keratinocytes, Kupffer cells, intestinal epithelial cells, and osteoblasts. | ||
| A2609 | Clazakizumab (Anti-IL-6 / IFNb2) | Clazakizumab (Anti-IL-6 / IFNb2) is a monoclonal antibody targeting the IL-6 (interleukin-6). It inhibitsg the cytokine response to SARS-CoV-2 in COVID-19 and can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection. MW :145.24 KD. | ||
| A2423 | Enokizumab (Anti-IL-9) | Enokizumab (Anti-IL-9) is a humanized monoclonal antibody directed against the cytokine interleukin-9 (IL-9), with potential immunomodulating activity. MW: 145.5 kD. | ||
| A2610 | Vobarilizumab (Anti-IL-6Ra / CD126) | Vobarilizumab (Anti-IL-6Ra / CD126) is a monoclonal antibody targeting IL-6R. It can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. MW :78.2 KD. | ||
| A2866 | Vunakizumab (Anti-CTLA-8 / IL-17a) | Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28. | ||
| A2428 | Mepolizumab (Anti-IL-5) | Mepolizumab (Anti-IL-5) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. MW: 145.5 kD. | ||
| A2430 | Pascolizumab (Anti-IL-4) | Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD. | ||
| A2432 | Itepekimab (Anti-IL-33) | Itepekimab (Anti-IL-33) is a monoclonal antibody against IL-33. Itepekimab reduces airway inflammation and related tissue damage in previous clinical studies. MW: 145.5 kD. | ||
| A2434 | Daclizumab (Anti-IL-2Ra / CD25) | Daclizumab (Anti-IL-2Ra / CD25) is a recombinant monoclonal antibody interleukin-2 receptor antagonist. MW:145.5 KD. | ||
| A2435 | Basiliximab (Anti-IL-2Ra / CD25) | Basiliximab (Anti-IL-2Ra / CD25) is a recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. MW:145.58 KD. | ||
| A2437 | Tildrakizumab (Anti-IL-23a) | Tildrakizumab (Anti-IL-23a) is a humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. MW:145.5 KD. | ||
| A2438 | Guselkumab (Anti-IL-23) | Guselkumab (Anti-IL-23) is a recombinant human IgG1 monoclonal antibody. It targets the key IL-23 and inhibits the production of cytokines lying downstream of the IL-23 signaling pathway and can be used for reatment of psoriatic arthritis, Crohn's disease, and ulcerative colitis. MW : 145.5 KD. |
|
|
| A2439 | Anti-IL-22Ra | Anti-IL-22Ra is an affinity isolated polyclonal antibody, targeting IL-22R. It is used in the treatment of psoriasis, psoriatic arthritis, atopic dermatitis. MW :145.5 KD. | ||
| S0777 | Isuzinaxib (APX-115 free base) | APX-115 free base (Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney. | ||
| A2440 | Fezakinumab (Anti-IL-22) | Fezakinumab (Anti-IL-22) is a monoclonal antibody targeting IL-22. It can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis. MW :145.5 KD. | ||
| A2883 | Gevokizumab (Anti-IL-1b) | Gevokizumab (Anti-IL-1b) is an IgG2 humanized monoclonal antibody against the pro-inflammatory cytokine interleukin 1 beta (IL-1b) with anti-inflammatory activity. MW: 145.12 KD. | ||
| A2441 | Fletikumab (Anti-IL-20) | Fletikumab (Anti-IL-20) is a monoclonal antibody, targeting IL-20. It can be used for inflammation research, such as rheumatoid arthritis and psoriasis. MW : 145.5 KD. | ||
| E0008 | Atractylodin | Atractylodin (Atractydin) is one of the major constituents of the rhizome of Atractylodes lancea and inhibits N-acylethanolamine-hydrolyzing acid amidase (NAAA) activity with an IC50 of 2.81 µM. Atractylodin also inhibits interleukin-6 (IL-6) by blocking NPM-ALK activation and MAPKs. | ||
| A2442 | Spesolimab (Anti-IL-1RL2 / IL-36R) | Spesolimab (Anti-IL-1RL2 / IL-36R) is an humanized antagonistic monoclonal antibody targeting IL-36 receptor. It can be used for treatment of palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP). MW : 145.5 KD. | ||
| A2443 | Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) | Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. It has the potential for chronic obstructive pulmonary disease (COPD), asthama treatment. MW :145.5 KD | ||
| S0781 | IQ 3 | IQ 3 is a specific c-Jun N-terminal kinase (JNK) inhibitor with Kd of 66 nM, 240 nM and 290 nM for JNK3, JNK1 and JNK2, respectively. IQ 3 inhibits LPS-induced NF-κB/AP1 transcriptional activity in THP1-Blue cells with IC50 of 1.4 μM. IQ 3 also inhibits TNF-α and IL-6 production in vitro. | ||
| A2444 | Nidanilimab (Anti-IL-1RAP / IL-1R3) | Nidanilimab (Anti-IL-1RAP / IL-1R3) is a fully humanized monoclonal antibody targeting IL1RAP and blocks IL1α and IL1β signaling. It also stimulates the immune system to destroy tumour cells. It can be used in treatment of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). MW :143.56 KD. | ||
| A2446 | Canakinumab (Anti-IL-1b) | Canakinumab (Anti-IL-1b) is a recombinant human anti-IL-1β monoclonal antibody targeting IL-1β and neutralizing IL-1β signaling. It can be used in treatment of disorders of autoimmune origin like familial mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome (TRAPS). MW :145.5 KD. | ||
| A2447 | Bermekimab (Anti-IL-1a) | Bermekimab (Anti-IL-1a) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). It prevents tumour-related inflammation. MW :145.5 KD. | ||
| A2448 | Anti-IL-18 | Anti-IL-18 is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD). MW :150 KD. | ||
| A2451 | Ordesekimab (Anti-IL-15) | Ordesekimab (Anti-IL-15) is a fully human monoclonal antibody targeting IL-15 and inhibiting the interaction of IL-15 with the IL-2Rβ. It has the potential for treatment of nonresponsive celiac disease (NRCD). MW :143.82 KD. | ||
| A2453 | Tralokinumab (Anti-IL-13) | Tralokinumab (Anti-IL-13) is a fully human IgG4 monoclonal antibody specifically targeting IL-13 with high affinity. It can be used for the research of the atopic dermatitis (AD). MW :145.5 KD. | ||
| A2454 | Abrezekimab (Anti-IL-13) | Abrezekimab (anti-IL-13) is a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. It can be used in research of asthma. MW: 145.5 KD. | ||
| A2038 | Dupilumab (anti-IL-4Rα) | Dupilumab (anti-IL-4Rα) is a fully human anti–interleukin-4 receptor α monoclonal antibody that inhibits both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling through blockade of the shared IL-4α subunit. | ||
| S6579 | RCGD423 | RCGD-423 is a modulator of Glycoprotein 130 (gp130, IL6ST, IL6-beta, CD130) signalling that regulates cartilage growth and differentiation. | ||
| S5973 | Methylprednisolone Acetate | Methylprednisolone (NSC-19987, Medrol) acetate is a synthetic glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation. Methylprednisolone activates ACE2 and reduces IL-6 levels, thus improves severe or critical COVID-19. Methylprednisolone markedly reduces autophagy and apoptosis. | ||
| A2118 | Anti-mouse IL-6-InVivo | Anti-mouse IL-6-InVivo monoclonal antibody (Clone:MP5-20F3) can reacts with mouse IL-6 (interleukin-6) which is a 21-28 kDa cytokine that is expressed by many cell types, including T lymphocytes, B lymphocytes, monocytes, fibroblasts, and endothelial cells. Anti-mouse IL-6-InVivo has been shown to neutralize the bioactivity of natural or recombinant IL-6. |
|
|
| S4966 | 4-Methylesculetin | 4-methylesculetin is one of the coumarin derivatives with great anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits myeloperoxidase (MPO) activity and reduces IL-6 level. | ||
| A2916 | Anti-GD2 (EMD 273063) | Anti-GD2 (EMD 273063) is a humanized immunoglobulin G1 (IgG1) anti-GD2 monoclonal antibody directed against the human pro-inflammatory cytokine interleukin (IL)-2 with potential antineoplastic and immunomodulatory activities. MW: 144.84 KD. | ||
| S9054 | Pectolinarin | Pectolinarin is a major compound in Cirsium setidens with anti-inflammatory activity. Pectolinarin inhibits secretion of IL-6 and IL-8, as well as the production of PGE2 and NO. Pectolinarin induces apoptosis via inactivation of the PI3K/Akt pathway. | ||
| E1153 | LMT-28 | LMT-28 is a novel synthetic interleukin-6 (IL-6) inhibitor that functions through direct binding to gp130. | ||
| S3293 | Gardenoside | Gardenoside is a natural compound extracted from Gardenia fruits, with hepatoprotective properties. Gardenoside inhibits TNF-α, IL-1β, IL-6 and NFκB activation. Gardenoside also has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis. Gardenoside suppresses the pain in rats model of chronic constriction injury by regulating the P2X3 and P2X7 receptors. | ||
| A2946 | Anti-IL-10 (BT-063) | Anti-IL-10 (BT-063) is a human monoclonal antibody directed against the human interleukin 10 (IL-10). It has the potential to be used in the treatment of systemic lupus erythematosus (SLE). MW: 145.74 KD. | ||
| A2947 | Briakinumab (Anti-IL-12) (IL-12a & IL-12b) | Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 KD. | ||
| A2949 | Cendakimab (Anti-IL-13) | Cendakimab (anti-IL-13) is a humanized, recombinant monoclonal antibody against the interleukin-13 (IL-13) molecule with the potential to treat allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). MW: 146.44 KD. | ||
| S9660 | Remibrutinib | Remibrutinib is a potent, highly selective covalent inhibitor of bruton tyrosine kinase (BTK) with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced IL8 and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases. | ||
| A2950 | Dectrekumab (Anti-IL-13) | Dectrekumab (anti-IL-13) is a humanized monoclonal antibody that targets interleukin-13 (IL-13). It has the potential to be used in inflammation and immunology-related research. MW: 146.16 KD. | ||
| S0139 | MD2-TLR4-IN-1 | MD2-TLR4-IN-1 (Compound 22m) is a potent inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4). MD2-TLR4-IN-1 (compound 22m) inhibits lipopolysaccharide (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with IC50 of 0.89 μM and 0.53 μM, respectively. | ||
| A2951 | Anti-IL-13 (GSK 679586) | Anti-IL-13 (GSK 679586) is a humanized monoclonal IgG1 antibody against interleukin-13 (IL-13). It has the potential to treat chronic spontaneous urticaria. MW: 148.38 KD. | ||
| A2952 | Anti-IL-13 (H2L6) | Anti-IL-13 (H2L6) is a humanized antibody against interleukin-13 (IL-13). MW: 146.16 KD. | ||
| A2953 | Anti-IL-13 (IMA-026) | Anti-IL-13 (IMA-026) is a humanized IgG1 antibody targated against interleukin 13 (IL-13) with the potential to treat chronic spontaneous urticaria. MW: 146.88 KD. | ||
| A2954 | Lebrikizumab (Anti-IL-13) | Lebrikizumab (anti-IL-13) is an humanized IgG4 monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. MW: 145.8 KD. | ||
| A2955 | Anti-IL-13 (M1295) | Anti-IL-13 (M1295) is a humanized antibody against interleukin-13 (IL-13). MW: 145.8 KD. | ||
| A2958 | Anti-IL-15 (DISC0280) | Anti-IL-15 (DISC0280) is a human monoclonal antibody targated againts Interleukin-15 (IL-15). MW: 145.62 KD. | ||
| A2959 | Anti-IL-18 (ABT-325) | Anti-IL-18 (ABT-325) is a humanized monoclonal antibody targeted against interleukin-18 (IL-18) with the potential to treat autoimmune diseases. MW: 146.28 KD. | ||
| A2960 | Anti-IL-1b (CDP484) | Anti-IL-1b (CDP484) is an antibody targated against Interleukin-1beta (IL-1b), a cytokine that initiates inflammatory cascades. MW: 145.74 KD. | ||
| A2962 | Melrilimab (Anti-IL-1RL1 / ST2 / IL-33R) | Melrilimab (anti-IL-1RL1/ ST2 / IL-33R) is an anti-ST2 (IL-1RL) monoclonal antibody targeting the IL-33 receptor. Melrilimab has the potential to be used in asthma research. MW: 145.2 KD. | ||
| A2964 | Avizakimab (Anti-IL-21) | Avizakimab (Anti-IL-21) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets interleukin-21. MW: 145.42 KD. | ||
| S9075 | Mulberroside A | Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. Mulberroside A decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38. | ||
| A2965 | Brazikumab (Anti-IL-23) | Brazikumab (Anti-IL-23) is a human IgG2 monoclonal antibody that selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for research on Crohn's disease. MW: 144.82 KD. | ||
| A2966 | Anti-IL-23 (LY2525623) | Anti-IL-23 (LY2525623) is a human monoclonal antibody targeting Interleukin-23 (IL-23). It has the potential to be researched for autoimmune inflammatory diseases. MW: 144.26 KD. | ||
| A2967 | Mirikizumab (Anti-IL-23) | Mirikizumab (Anti-IL-23) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23. Mirikizumab can be used for research on ulcerative colitis. MW: 144.26 KD. | ||
| A2968 | Camidanlumab (Anti-IL-2Ra / CD25) | Camidanlumab (HuMax-TAC) is a human IgG1 monoclonal antibody directed against CD25 (IL-2R alpha), which is overexpressed in a variety of hematological tumors. MW: 143.98 KD. | ||
| A2972 | Anti-IL-4Ra / CD124 (MEDI2045) | Anti-IL-4Ra / CD124 (MEDI2045) is a high-affinity human and Cynomolgus cross-reactive antibody that blocks the functional interaction of IL-4 and IL-13 with their obligate receptor, IL-4Ra. MEDI 2045 has the potential to treat severe, uncontrolled asthma. MW: 143.76 KD. | ||
| A2973 | Anti-IL-5 (Abgenix anti-IL-5) | Anti-IL-5 (Abgenix anti-IL-5) is a human monoclonal antibody against interleukin-5. MW: 145.0 KD. | ||
| A2163New | Anti-mouse IL-12 p40-InVivo | |||
| A2975 | Anti-IL-6 / IFNb2 (Chugai SK2) | Anti-IL-6 / IFNb2 (Chugai SK2) is a humanized mouse monoclonal antibody that specifically binds to IL-6 and strongly inhibits IL-6 functions. MW: 145.46 KD. | ||
| A2978 | Anti-IL-6 / IFNb2 (MEDI 5117) | Anti-IL-6/IFNb2 (MEDI 5117) is a human monoclonal antibody against Interleukin-6 (IL-6), a pleiotropic cytokine with immune regulation, inflammation, and oncogenesis. It has the potential to treat rheumatoid arthritis (RA). MW: 145.14 KD. | ||
| A2980 | Sirukumab (Anti-IL-6 / IFNb2) | Sirukumab (Anti-IL-6 / IFNb2) is a humanized monoclonal IgG1κ antibody targeting IL6 (Interleukin Related). It has the potential for active lupus nephritis research. MW :144.58 KD. | ||
| A2981 | Ziltivekimab (Anti-IL-6 / IFNb2) | Ziltivekimab (Anti-IL-6 / IFNb2) is a human monoclonal antibody targeting IL-6. It has anti-inflammatory activity and may be used in studies of chronic systemic inflammation and cardiovascular disease associated with CKD. MW :145.14 KD. | ||
| A2982 | Anti-IL-6Ra / CD126 (APX007) | Anti-IL-6Ra / CD126 (APX007) is a monoclonal antibody targeting IL-6R/CD126. It can be used in the pathogenesis of multiple myeloma. MW :144.6 KD. | ||
| S6850 | NE 52-QQ57 | NE 52-QQ57 is a selective, and orally available antagonist of G-protein coupled receptor 4 (GPR4) with IC50 of 0.07 μM. NE 52-QQ57 effectively blocks GPR4-mediated cAMP accumulation with IC50 of 26.8 nM in HEK293 cells. The antagonism of GPR4 with NE 52-QQ57 significantly inhibits the AGE-induced increased expression of several key inflammatory cytokines and signaling molecules, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, inducible nitric oxide synthase (iNOS), nitric oxide (NO), cyclooxygenase 2 (COX2), and prostaglandin E2 (PGE2). | ||
| A2983 | Levilimab (Anti-IL-6Ra / CD126) | Levilimab (Anti-IL-6Ra / CD126) is a fully human monoclonal antibody targeting interleukin-6 receptor (IL-6R). It is an inflammation-alleviating antibody and can be used for the research of rheumatoid arthritis and covid-19 treatment. MW :145.62 KD. | ||
| A2984 | Sapelizumab (Anti-IL-6Ra / CD126) | Sapelizumab (Anti-IL-6Ra / CD126) is a human monoclonal antibody targeting IL-6. It is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. MW :144.26 KD. | ||
| A2985 | Olokizumab (Anti-IL-6 / IFNb2) | Olokizumab (Anti-IL-6 / IFNb2) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). It can be used in research of rheumatoid arthritis (RA). MW :145.4 KD. | ||
| S9417 | Homoplantaginin | Homoplantaginin (Hispidulin-7-glucoside), a main flavonoid from a traditional Chinese medicine Salvia plebeia, has anti-inflammatory and anti-oxidant properties. Homoplantaginin inhibits TNF-α and IL-6 mRNA expression, IKKβ and NF-κB phosphorylation. | ||
| S5579 | Chelidonic acid | Chelidonic acid (Jerva acid, Jervaic acid, γ-Pyrone-2,6-dicarboxylic acid) is a secondary metabolite found in several plants with therapeutic potential in allergic disorders in experimental animals. Chelidonic acid inhibits IL-6 production by blocking NF-κB and caspase-1 in HMC-1 cells. Chelidonic acid is also an inhibitor of glutamate decarboxylase with Ki of 1.2 μM. | ||
| E2630 | SKF-86002 | SKF-86002 is an orally active p38 MAPK inhibitor, inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production with IC50 of 1 μM, also inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. | ||
| S6347 | 5'-N-Ethylcarboxamidoadenosine (NECA) | 5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway. | ||
| S9129 | 20(S)-Ginsenoside Rh1 | 20(S)-Ginsenoside Rh1 (Prosapogenin A2, Sanchinoside B2, Sanchinoside Rh1) is one of major bioactive compounds extracted from red ginseng, which has been increasingly used for enhancing cognition and physical health worldwide. It exhibits potent characteristics of anti-inflammatory, antioxidant, immunomodulatory effects, and positive effects on the nervous system. Ginsenoside Rh1 inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β. | ||
| A2138 | Anti-mouse IL-2-InVivo | Anti-mouse IL-2-InVivo reacts with mouse IL-2, a cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation. | ||
| S3138 | Methylthiouracil | Methylthiouracil (NSC-193526, NSC-9378,MTU) is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2. | ||
| E0177 | Hydrocortisone sodium succinate | Hydrocortisone sodium succinate (Hydrocortisone 21-hemisuccinate sodium salt) has significant inhibitory effects on the IL-6 bioactivity with IC50 of 6.7 μM. Hydrocortisone sodium succinate can bind to glucocorticoid receptor, initiating the transcription of anti-inflammatory and immunosuppressive mediators. | ||
| S6727 | AX-024 HCl | AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A. | ||
| S3261 | Myrislignan | Myrislignan, a lignan isolated from Myristica fragrans Houtt, possesses anti-inflammatory activities. Myrislignan inhibits interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α). Myrislignan significantly inhibits the expressions of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) dose-dependently in LPS-stimulated macrophage cells. Myrislignan inhibits the NF-κB signalling pathway activation. | ||
| S0228 | SU 5201 | SU 5201 (NSC 247030) is an interleukin-2 (IL-2) inhibitor. | ||
| S3304 | Stylopine | Stylopine ((R,S)-Stylopine, Tetrahydrocoptisine) reduces nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), and the IL-6 production and cyclooxygenase-2 (COX-2) activity caused by the LPS stimulation. Stylopine is a major component of the leaf of Chelidonium majus L. | ||
| A2797 | Anti-IL-25 | Anti-IL-25 is a humanised monoclonal antibody against Interleukin-25 (IL-25) with the potential to treat airway hyperresponsiveness (AHR). MW: 146.02 KD. | ||
| A2801 | Anti-IL-13 (CNTO 607) | Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD. | ||
| S9184 | Forsythoside B | Forsythoside B is a phenylethanoid glycoside isolated from the leaves of Lamiophlomis rotata Kudo, a Chinese folk medicinal plant. Forsythoside B has potent neuroprotective effects and has anti-inflammation, antioxidant, and antisepsis properties. Forsythoside B could inhibit TNF-alpha, IL-6, IκB and modulate NF-κB. | ||
| A2030 | Siltuximab (anti-IL-6) | Siltuximab (anti-IL-6) (CNTO 328) is a human-mouse chimeric monoclonal antibody that binds human interleukin-6 (IL-6). | ||
| S3299 | Demethyleneberberine | Demethyleneberberine (DMB), a component of Cortex Phellodendri Chinensis (CPC), significantly alleviates the weight loss and diminishes myeloperoxidase (MPO) activity, while significantly reduces the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α), and inhibits the activation of NF-κB signaling pathway. Demethyleneberberine (DMB) potentially ameliorates NAFLD (Non-alcoholic fatty liver disease) by activating AMPK pathways. | ||
| A2032 | Brodalumab (anti-IL17RA) | Brodalumab (anti-IL17RA) (KHK4827, AMG 827) is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). | ||
| S8133 | Resiquimod (R-848) | Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2. | ||
| S7455 | Resatorvid (TAK-242) | Resatorvid (TAK-242, CLI-095) is a small-molecule-specific inhibitor of Toll-like receptor (TLR) 4 signaling, blocking LPS-induced production of NO, TNF-α and IL-6 in macrophages with IC50 of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy. | ||
| S1189 | Aprepitant | Aprepitant is a potent and selective neurokinin-1 receptor antagonist with IC50 of 0.1 nM. Aprepitant reduces levels of pro-inflammatory cytokines including G-CSF, IL-6, IL-8 and TNFα. Aprepitant inhibits HIV infection of human macrophages. |
|
|
| S8966 | T-5224 | T-5224 is a selective inhibitor of transcription factor c-Fos/activator protein (AP)-1 with anti-inflammatory effects. T-5224 specifically inhibits the DNA binding activity of c-Fos/c-Jun and the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription. | ||
| S6414 | Apilimod | Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod (STA-5326) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod (STA-5326) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM. | ||
| S7259 | FLLL32 | FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells. |
|
|
| S8301 | Ossirene (AS101) | Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta converting enzyme. | ||
| S4267 | Diacerein | Diacerein is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis. |
|
|
| S1733 | Methylprednisolone | Methylprednisolone (NSC-19987,U 7532) is a synthetic glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation. Methylprednisolone activates ACE2 and reduces IL-6 levels, thus improves severe or critical COVID-19. Methylprednisolone markedly reduces autophagy and apoptosis. |
|
|
| S9727 | Ac-YVAD-cmk | Ac-YVAD-cmk (Caspase-1 Inhibitor II) is a selective IL-1β converting enzyme (ICE) inhibitor with neuroprotective and anti-inflammatory effects, effectively suppresses the expression of IL-1β and IL-18. | ||
| S8261 | GSK583 | GSK583 is a highly potent and selective inhibitor of RIP2 kinase with IC50 of 5 nM. GSK583 also inhibits both TNF-α and IL-6 production with IC50 of ~200 nM in explant cultures. | ||
| S0785 | Apilimod mesylate | Apilimod mesylate is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. Apilimod mesylate (STA-5326 mesylate) inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. Apilimod mesylate (STA-5326 mesylate) is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM. | ||
| S0787 | 3-Deazaadenosine hydrochloride | 3-Deazaadenosine HCl (3-DZA, c3Ado) is a potent inhibitor of S-adenosylhomocysteine hydrolase with Ki of 3.9 µM. 3-Deazaadenosine HCl inhibits bacterial lipopolysaccharide-induced transcription of TNF-α and IL-1β. 3-Deazaadenosine HCl inhibits the transcriptional activity of NF-κB, prevents FCS-induced Ras carboxyl methylation and reduces FCS-induced ERK1/2 and Akt phosphorylation. 3-Deazaadenosine HCl has anti-inflammatory, anti-proliferative and anti-HIV activities. | ||
| S3292 | Falcarindiol | Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules. | ||
| S9668 | PKR-IN-C16 | PKR-IN-C16 (C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component. | ||
| S8879 | Deucravacitinib (BMS-986165) | Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases. | ||
| S0826 | A-740003 | A-740003 is a potent, selective and competitive antagonist of P2X7 receptor with IC50 of 18 nM and 40 nM for rat and human P2X7 receptors, respectively. A-740003 potently blocks agonist-evoked IL-1β release and pore formation with IC50 of 156 nM and 92 nM in differentiated human THP-1 cells. | ||
| S6898 | RCM-1 | RCM-1 is a nontoxic inhibitor of Forkhead box M1 (FOXM1) that suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. RCM-1 decreases carcinogenesis and nuclear β-catenin. | ||
| S5972 | Hydrocortisone hemisuccinate | Hydrocortisone hemisuccinate (A-hydrocort, Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid with anti-inflammatory properties, is an inhibitor of proinflammatory cytokine with IC50 of 6.7 μM and 21.4 μM for Interleukin-6 (IL-6) and IL-3, respectively. | ||
| S9052 | Auraptene | Auraptene (7-geranyloxycoumarin) is a natural coumarin derived from citrus plants and possesses valuable pharmacological properties, including anticarcinogenic, anti-inflammatory, antihelicobacter, antigenotoxic, and neuroprotective effects. Auraptene inhibits matrix metalloproteinase 2 (MMP-2) as well as key inflammatory mediators, including IL-6, IL-8 and chemokine (C-C motif) ligand-5(CCL5). | ||
| S9374 | 2',5'-Dihydroxyacetophenone | 2',5'-Dihydroxyacetophenone (DHAP, 2-Acetylhydroquinone, Quinacetophenone) is a mixture of dihydroxyacetophenone isomers is used in food flavouring. 2',5'-Dihydroxyacetophenone significantly inhibits NO production via the suppression of iNOS expression. 2',5'-Dihydroxyacetophenone significantly decreases levels of the pro-inflammatory cytokines TNF-α and IL-6 by blocking the ERK1/2 and NF-κB signaling pathways. | ||
| S3871 | Muscone | Muscone (3-Methylcyclopentadecanone, Methylexaltone), a flavouring ingredient, is an organic compound that is the primary contributor to the odor of musk and also a potent anti-inflammatory agent. Muscone significantly downregulats the levels of LPS-induced inflammatory cytokines and inhibits NF-κB and NLRP3 inflammasome activation in BMDMs. Muscone remarkably decreases the levels of inflammatory cytokines (IL-1β, TNF-α and IL-6). | ||
| S6620 | Danirixin (GSK1325756) | Danirixin (GSK1325756) is a small molecule, non-peptide, high affinity (IC50 for CXCL8 (IL-8) binding = 12.5 nM), selective, and reversible CXCR2 antagonist. | ||
| S0437 | SAR-20347 | SAR-20347 is a potent inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediated IL-12 and IFN-α signaling. | ||
| S9502 | Madecassic acid | Madecassic acid (Brahmic acid), a natural triterpene first isolated from C. asiatica, has diverse anti-inflammatory and anti-diabetic effects, blocking NF-κB activation in macrophages and causing by iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 inhibition. | ||
| S0472 | EC330 | EC330 is a steroidal inhibitor of leukemia inhibitory factor (LIF, an interleukin 6 class cytokine). EC330 inhibits the LIF/LIF-R signaling and blocks the promoting effects of LIF on growth and migration of cancer cells. | ||
| S1833 | Butoconazole nitrate | Butoconazole nitrate (RS-35887) is an anti-fungal agent that inhibits PHA-stimulated release of cytokines-- IL-2, TNFα, IFN and GM-CSF from human peripheral blood lymphocytes (IC50 of 7.2 μg/mL, 14.4 μg/mL, 7.36 μg/mL and 7.6 μg/mL, respectively). | ||
| S3312 | Diethyl phosphate | Diethyl phosphate (DEP, DPF, Diethyl phosphoric acid, diethyl hydrogen phosphate), a non-specific metabolite of organophosphorus pesticides in the gut environment, significantly enriches opportunistic pathogens leading to a decrease in interleukin-6 (IL-6). |
||
| S5764 | YM 90709 | YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R). | ||
| S3590 | Triolein | Triolein is an inhibitor of metalloproteinase-1 (MMP-1) and reduces both the expression of IL-6 and ROS generation in irradiated keratinocytes. | ||
| E0314 | JTE-607 Dihydrochloride | JTE-607 Dihydrochloride is a prodrug compound that is converted to an active form by ester hydrolysis. JTE-607 is a multiple cytokine production inhibitor that targets CPSF3 and inhibits pre-mRNA processing. JTE-607 inhibits tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50 values of 11 nM, 5.9 nM, 8.8 nM, 7.3 nM and 9.1 nM, respectively. |
||
| S3969 | Veratric acid | Veratric acid (3,4-Dimethoxybenzoic acid), a simple benzoic acid derived from plants and fruits, has anti-oxidant, anti-inflammation, and blood pressure-lowering effects. Veratric acid reduces upregulated COX-2 expression, and levels of PGE2, IL-6 after UVB irradiation. | ||
| S9236 | α-Cyperone | α-Cyperone (alpha-cyperone), a major active compound of Cyperus rotundus, exhibits biological activities, such as antivirulence, antigenotoxic, and antibacterial activities. α-Cyperone (alpha-cyperone) is associated with the down-regulation of COX-2, IL-6, Nck-2, Cdc42 and Rac1. | ||
| S0752 | AUDA | AUDA (compound 43) is a potent inhibitor of soluble epoxide hydrolase (sEH) with IC50 of 18 nM and 69 nM for the mouse sEH and human sEH, respectively. AUDA has anti-inflammatory activity that reduces the protein expression of MMP-9, IL-1β, TNF-α and TGF-β. AUDA downregulates Smad3 and p38 signaling pathways. | ||
| S0777 | Isuzinaxib (APX-115 free base) | APX-115 free base (Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney. | ||
| E0008 | Atractylodin | Atractylodin (Atractydin) is one of the major constituents of the rhizome of Atractylodes lancea and inhibits N-acylethanolamine-hydrolyzing acid amidase (NAAA) activity with an IC50 of 2.81 µM. Atractylodin also inhibits interleukin-6 (IL-6) by blocking NPM-ALK activation and MAPKs. | ||
| S0781 | IQ 3 | IQ 3 is a specific c-Jun N-terminal kinase (JNK) inhibitor with Kd of 66 nM, 240 nM and 290 nM for JNK3, JNK1 and JNK2, respectively. IQ 3 inhibits LPS-induced NF-κB/AP1 transcriptional activity in THP1-Blue cells with IC50 of 1.4 μM. IQ 3 also inhibits TNF-α and IL-6 production in vitro. | ||
| S5973 | Methylprednisolone Acetate | Methylprednisolone (NSC-19987, Medrol) acetate is a synthetic glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation. Methylprednisolone activates ACE2 and reduces IL-6 levels, thus improves severe or critical COVID-19. Methylprednisolone markedly reduces autophagy and apoptosis. | ||
| S4966 | 4-Methylesculetin | 4-methylesculetin is one of the coumarin derivatives with great anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits myeloperoxidase (MPO) activity and reduces IL-6 level. | ||
| S9054 | Pectolinarin | Pectolinarin is a major compound in Cirsium setidens with anti-inflammatory activity. Pectolinarin inhibits secretion of IL-6 and IL-8, as well as the production of PGE2 and NO. Pectolinarin induces apoptosis via inactivation of the PI3K/Akt pathway. | ||
| E1153 | LMT-28 | LMT-28 is a novel synthetic interleukin-6 (IL-6) inhibitor that functions through direct binding to gp130. | ||
| S3293 | Gardenoside | Gardenoside is a natural compound extracted from Gardenia fruits, with hepatoprotective properties. Gardenoside inhibits TNF-α, IL-1β, IL-6 and NFκB activation. Gardenoside also has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis. Gardenoside suppresses the pain in rats model of chronic constriction injury by regulating the P2X3 and P2X7 receptors. | ||
| S9660 | Remibrutinib | Remibrutinib is a potent, highly selective covalent inhibitor of bruton tyrosine kinase (BTK) with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced IL8 and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases. | ||
| S0139 | MD2-TLR4-IN-1 | MD2-TLR4-IN-1 (Compound 22m) is a potent inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4). MD2-TLR4-IN-1 (compound 22m) inhibits lipopolysaccharide (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with IC50 of 0.89 μM and 0.53 μM, respectively. | ||
| S9075 | Mulberroside A | Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. Mulberroside A decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38. | ||
| S6850 | NE 52-QQ57 | NE 52-QQ57 is a selective, and orally available antagonist of G-protein coupled receptor 4 (GPR4) with IC50 of 0.07 μM. NE 52-QQ57 effectively blocks GPR4-mediated cAMP accumulation with IC50 of 26.8 nM in HEK293 cells. The antagonism of GPR4 with NE 52-QQ57 significantly inhibits the AGE-induced increased expression of several key inflammatory cytokines and signaling molecules, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, inducible nitric oxide synthase (iNOS), nitric oxide (NO), cyclooxygenase 2 (COX2), and prostaglandin E2 (PGE2). | ||
| S9417 | Homoplantaginin | Homoplantaginin (Hispidulin-7-glucoside), a main flavonoid from a traditional Chinese medicine Salvia plebeia, has anti-inflammatory and anti-oxidant properties. Homoplantaginin inhibits TNF-α and IL-6 mRNA expression, IKKβ and NF-κB phosphorylation. | ||
| S5579 | Chelidonic acid | Chelidonic acid (Jerva acid, Jervaic acid, γ-Pyrone-2,6-dicarboxylic acid) is a secondary metabolite found in several plants with therapeutic potential in allergic disorders in experimental animals. Chelidonic acid inhibits IL-6 production by blocking NF-κB and caspase-1 in HMC-1 cells. Chelidonic acid is also an inhibitor of glutamate decarboxylase with Ki of 1.2 μM. | ||
| E2630 | SKF-86002 | SKF-86002 is an orally active p38 MAPK inhibitor, inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production with IC50 of 1 μM, also inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. | ||
| S6347 | 5'-N-Ethylcarboxamidoadenosine (NECA) | 5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway. | ||
| S9129 | 20(S)-Ginsenoside Rh1 | 20(S)-Ginsenoside Rh1 (Prosapogenin A2, Sanchinoside B2, Sanchinoside Rh1) is one of major bioactive compounds extracted from red ginseng, which has been increasingly used for enhancing cognition and physical health worldwide. It exhibits potent characteristics of anti-inflammatory, antioxidant, immunomodulatory effects, and positive effects on the nervous system. Ginsenoside Rh1 inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β. | ||
| S3138 | Methylthiouracil | Methylthiouracil (NSC-193526, NSC-9378,MTU) is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2. | ||
| E0177 | Hydrocortisone sodium succinate | Hydrocortisone sodium succinate (Hydrocortisone 21-hemisuccinate sodium salt) has significant inhibitory effects on the IL-6 bioactivity with IC50 of 6.7 μM. Hydrocortisone sodium succinate can bind to glucocorticoid receptor, initiating the transcription of anti-inflammatory and immunosuppressive mediators. | ||
| S6727 | AX-024 HCl | AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A. | ||
| S3261 | Myrislignan | Myrislignan, a lignan isolated from Myristica fragrans Houtt, possesses anti-inflammatory activities. Myrislignan inhibits interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α). Myrislignan significantly inhibits the expressions of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) dose-dependently in LPS-stimulated macrophage cells. Myrislignan inhibits the NF-κB signalling pathway activation. | ||
| S0228 | SU 5201 | SU 5201 (NSC 247030) is an interleukin-2 (IL-2) inhibitor. | ||
| S3304 | Stylopine | Stylopine ((R,S)-Stylopine, Tetrahydrocoptisine) reduces nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), and the IL-6 production and cyclooxygenase-2 (COX-2) activity caused by the LPS stimulation. Stylopine is a major component of the leaf of Chelidonium majus L. | ||
| S9184 | Forsythoside B | Forsythoside B is a phenylethanoid glycoside isolated from the leaves of Lamiophlomis rotata Kudo, a Chinese folk medicinal plant. Forsythoside B has potent neuroprotective effects and has anti-inflammation, antioxidant, and antisepsis properties. Forsythoside B could inhibit TNF-alpha, IL-6, IκB and modulate NF-κB. | ||
| S3299 | Demethyleneberberine | Demethyleneberberine (DMB), a component of Cortex Phellodendri Chinensis (CPC), significantly alleviates the weight loss and diminishes myeloperoxidase (MPO) activity, while significantly reduces the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α), and inhibits the activation of NF-κB signaling pathway. Demethyleneberberine (DMB) potentially ameliorates NAFLD (Non-alcoholic fatty liver disease) by activating AMPK pathways. | ||
| A2025 | Secukinumab (anti-IL-17A) | Secukinumab (anti-IL-17A) (Cosentyx, AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa. | ||
| A2120 | Anti-mouse IL-17A-InVivo | Anti-mouse IL-17A-InVivo monoclonal antibody (Clone:17F3) reacts with mouse IL-17A which is a 15-20 kDa cytokine expressed by Th17 cells, γδ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells. Anti-mouse IL-17A-InVivo has been shown to neutralize IL-17A in vivo. |
|
|
| A2375 | Rolinsatamab (Anti-PRLR / Prolactin Receptor) | Rolinsatamab (Anti-PRLR / Prolactin Receptor) is a fully humanized bispecific monoclonal antibody that targets IL-4 and IL-13. MW: 145.5 kD. | ||
| A2822 | Depemokimab (Anti-IL-5) | Depemokimab (Anti-IL-5) is a humanized monoclonal antibody (IgG1, kappa) directed against IL-5. Depemokimab can be used for research of asthma. MW : 145.8 KD. | ||
| A2142New | Anti-mouse/rat IL-1β-InVivo | Anti-mouse/rat IL-1β-InVivo reacts with precursor and mature secreted forms of mouse and rat IL-1β a 17 kDa pro-inflammatory cytokine produced primarily by monocytes. | ||
| A2842 | Ebdarokimab (Anti-IL-12b) | Ebdarokimab (Anti-IL-12b) is a fully human monoclonal antibody (mAb) targeting Interleukin-12/Interleukin-23 (IL-12/IL-23) pathway. Ebdarokimab has the potential to treat moderate to severe plaque psoriasis. MW : 145.6 KD. | ||
| A2153New | Anti-mouse IL-2 (S4B6-1)-InVivo | Anti-mouse IL-2 (S4B6-1)-InVivo reacts with mouse IL-2, a 17 kDa cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation. | ||
| A2845 | Elsilimomab (Anti-IL-6 / IFNb2) | Elsilimomab (Anti-IL-6 / IFNb2) is an IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab has the potential to be used in research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). MW : 145.96 KD. | ||
| A2157New | Anti-mouse IL-6R-InVivo | Anti-mouse IL-6R-InVivo reacts with the mouse IL-6 receptor α chain also known as CD126. CD126 is an 80 kDa type I cytokine receptor and a member of the immunoglobulin superfamily. | ||
| A2046 | Risankizumab (anti-IL-23) | Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease. |
|
|
| A2856 | Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7) | Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7) is a gut‐selective humanized monoclonal antibody targets β7 integrins with a potential to treat inflammatory bowel disease (IBD). MW: 144.3 KD. | ||
| A2861 | Anti-CTLA-8 / IL-17a (CAT-2200) | Anti-CTLA-8 / IL-17a (CAT-2200) is a human monoclonal antibody against IL-17A (interleukin-17A) that can potently neutralize the effects of recombinant and native human IL-17A. MW: 143.72. | ||
| A2862 | Ixekizumab (Anti-CTLA-8 / IL-17a) | Ixekizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab has the potential to be used in research on plaque psoriasis. MW: 146.44 KD. | ||
| A2863 | Netakimab (Anti-CTLA-8 / IL-17a) | Netakimab (Anti-CTLA-8 / IL-17a) is a humanized monoclonal antibody against interleukin-17 (IL-17) with the potential to treat moderate to severe plaque psoriasis. MW: 145.74 KD. | ||
| A2024 | Ustekinumab (anti-IL-12/IL-23) | Ustekinumab (CNTO 1275) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody used to treat psoriasis. MW=145.6 kDa. | ||
| A2864 | Perakizumab (Anti-CTLA-8 / IL-17a) | Perakizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG1κ monoclonal antibody against interleukin-17A (IL-17A). MW: 145.8 KD. | ||
| A2134 | Anti-mouse IL-18-InVivo | Anti-mouse IL-18-InVivo (Clone:YIGIF74-1G7) monoclonal antibody reacts with mouse IL-18. IL-18 an 18 kDa pro-inflammatory cytokine is expressed by activated macrophages, keratinocytes, Kupffer cells, intestinal epithelial cells, and osteoblasts. | ||
| A2609 | Clazakizumab (Anti-IL-6 / IFNb2) | Clazakizumab (Anti-IL-6 / IFNb2) is a monoclonal antibody targeting the IL-6 (interleukin-6). It inhibitsg the cytokine response to SARS-CoV-2 in COVID-19 and can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection. MW :145.24 KD. | ||
| A2423 | Enokizumab (Anti-IL-9) | Enokizumab (Anti-IL-9) is a humanized monoclonal antibody directed against the cytokine interleukin-9 (IL-9), with potential immunomodulating activity. MW: 145.5 kD. | ||
| A2610 | Vobarilizumab (Anti-IL-6Ra / CD126) | Vobarilizumab (Anti-IL-6Ra / CD126) is a monoclonal antibody targeting IL-6R. It can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. MW :78.2 KD. | ||
| A2866 | Vunakizumab (Anti-CTLA-8 / IL-17a) | Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28. | ||
| A2428 | Mepolizumab (Anti-IL-5) | Mepolizumab (Anti-IL-5) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. MW: 145.5 kD. | ||
| A2430 | Pascolizumab (Anti-IL-4) | Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD. | ||
| A2432 | Itepekimab (Anti-IL-33) | Itepekimab (Anti-IL-33) is a monoclonal antibody against IL-33. Itepekimab reduces airway inflammation and related tissue damage in previous clinical studies. MW: 145.5 kD. | ||
| A2434 | Daclizumab (Anti-IL-2Ra / CD25) | Daclizumab (Anti-IL-2Ra / CD25) is a recombinant monoclonal antibody interleukin-2 receptor antagonist. MW:145.5 KD. | ||
| A2435 | Basiliximab (Anti-IL-2Ra / CD25) | Basiliximab (Anti-IL-2Ra / CD25) is a recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. MW:145.58 KD. | ||
| A2437 | Tildrakizumab (Anti-IL-23a) | Tildrakizumab (Anti-IL-23a) is a humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. MW:145.5 KD. | ||
| A2438 | Guselkumab (Anti-IL-23) | Guselkumab (Anti-IL-23) is a recombinant human IgG1 monoclonal antibody. It targets the key IL-23 and inhibits the production of cytokines lying downstream of the IL-23 signaling pathway and can be used for reatment of psoriatic arthritis, Crohn's disease, and ulcerative colitis. MW : 145.5 KD. |
|
|
| A2439 | Anti-IL-22Ra | Anti-IL-22Ra is an affinity isolated polyclonal antibody, targeting IL-22R. It is used in the treatment of psoriasis, psoriatic arthritis, atopic dermatitis. MW :145.5 KD. | ||
| A2440 | Fezakinumab (Anti-IL-22) | Fezakinumab (Anti-IL-22) is a monoclonal antibody targeting IL-22. It can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis. MW :145.5 KD. | ||
| A2883 | Gevokizumab (Anti-IL-1b) | Gevokizumab (Anti-IL-1b) is an IgG2 humanized monoclonal antibody against the pro-inflammatory cytokine interleukin 1 beta (IL-1b) with anti-inflammatory activity. MW: 145.12 KD. | ||
| A2441 | Fletikumab (Anti-IL-20) | Fletikumab (Anti-IL-20) is a monoclonal antibody, targeting IL-20. It can be used for inflammation research, such as rheumatoid arthritis and psoriasis. MW : 145.5 KD. | ||
| A2442 | Spesolimab (Anti-IL-1RL2 / IL-36R) | Spesolimab (Anti-IL-1RL2 / IL-36R) is an humanized antagonistic monoclonal antibody targeting IL-36 receptor. It can be used for treatment of palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP). MW : 145.5 KD. | ||
| A2443 | Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) | Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. It has the potential for chronic obstructive pulmonary disease (COPD), asthama treatment. MW :145.5 KD | ||
| A2444 | Nidanilimab (Anti-IL-1RAP / IL-1R3) | Nidanilimab (Anti-IL-1RAP / IL-1R3) is a fully humanized monoclonal antibody targeting IL1RAP and blocks IL1α and IL1β signaling. It also stimulates the immune system to destroy tumour cells. It can be used in treatment of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). MW :143.56 KD. | ||
| A2446 | Canakinumab (Anti-IL-1b) | Canakinumab (Anti-IL-1b) is a recombinant human anti-IL-1β monoclonal antibody targeting IL-1β and neutralizing IL-1β signaling. It can be used in treatment of disorders of autoimmune origin like familial mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome (TRAPS). MW :145.5 KD. | ||
| A2447 | Bermekimab (Anti-IL-1a) | Bermekimab (Anti-IL-1a) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). It prevents tumour-related inflammation. MW :145.5 KD. | ||
| A2448 | Anti-IL-18 | Anti-IL-18 is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD). MW :150 KD. | ||
| A2451 | Ordesekimab (Anti-IL-15) | Ordesekimab (Anti-IL-15) is a fully human monoclonal antibody targeting IL-15 and inhibiting the interaction of IL-15 with the IL-2Rβ. It has the potential for treatment of nonresponsive celiac disease (NRCD). MW :143.82 KD. | ||
| A2453 | Tralokinumab (Anti-IL-13) | Tralokinumab (Anti-IL-13) is a fully human IgG4 monoclonal antibody specifically targeting IL-13 with high affinity. It can be used for the research of the atopic dermatitis (AD). MW :145.5 KD. | ||
| A2454 | Abrezekimab (Anti-IL-13) | Abrezekimab (anti-IL-13) is a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. It can be used in research of asthma. MW: 145.5 KD. | ||
| A2038 | Dupilumab (anti-IL-4Rα) | Dupilumab (anti-IL-4Rα) is a fully human anti–interleukin-4 receptor α monoclonal antibody that inhibits both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling through blockade of the shared IL-4α subunit. | ||
| A2118 | Anti-mouse IL-6-InVivo | Anti-mouse IL-6-InVivo monoclonal antibody (Clone:MP5-20F3) can reacts with mouse IL-6 (interleukin-6) which is a 21-28 kDa cytokine that is expressed by many cell types, including T lymphocytes, B lymphocytes, monocytes, fibroblasts, and endothelial cells. Anti-mouse IL-6-InVivo has been shown to neutralize the bioactivity of natural or recombinant IL-6. |
|
|
| A2916 | Anti-GD2 (EMD 273063) | Anti-GD2 (EMD 273063) is a humanized immunoglobulin G1 (IgG1) anti-GD2 monoclonal antibody directed against the human pro-inflammatory cytokine interleukin (IL)-2 with potential antineoplastic and immunomodulatory activities. MW: 144.84 KD. | ||
| A2946 | Anti-IL-10 (BT-063) | Anti-IL-10 (BT-063) is a human monoclonal antibody directed against the human interleukin 10 (IL-10). It has the potential to be used in the treatment of systemic lupus erythematosus (SLE). MW: 145.74 KD. | ||
| A2947 | Briakinumab (Anti-IL-12) (IL-12a & IL-12b) | Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 KD. | ||
| A2949 | Cendakimab (Anti-IL-13) | Cendakimab (anti-IL-13) is a humanized, recombinant monoclonal antibody against the interleukin-13 (IL-13) molecule with the potential to treat allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). MW: 146.44 KD. | ||
| A2950 | Dectrekumab (Anti-IL-13) | Dectrekumab (anti-IL-13) is a humanized monoclonal antibody that targets interleukin-13 (IL-13). It has the potential to be used in inflammation and immunology-related research. MW: 146.16 KD. | ||
| A2951 | Anti-IL-13 (GSK 679586) | Anti-IL-13 (GSK 679586) is a humanized monoclonal IgG1 antibody against interleukin-13 (IL-13). It has the potential to treat chronic spontaneous urticaria. MW: 148.38 KD. | ||
| A2952 | Anti-IL-13 (H2L6) | Anti-IL-13 (H2L6) is a humanized antibody against interleukin-13 (IL-13). MW: 146.16 KD. | ||
| A2953 | Anti-IL-13 (IMA-026) | Anti-IL-13 (IMA-026) is a humanized IgG1 antibody targated against interleukin 13 (IL-13) with the potential to treat chronic spontaneous urticaria. MW: 146.88 KD. | ||
| A2954 | Lebrikizumab (Anti-IL-13) | Lebrikizumab (anti-IL-13) is an humanized IgG4 monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. MW: 145.8 KD. | ||
| A2955 | Anti-IL-13 (M1295) | Anti-IL-13 (M1295) is a humanized antibody against interleukin-13 (IL-13). MW: 145.8 KD. | ||
| A2958 | Anti-IL-15 (DISC0280) | Anti-IL-15 (DISC0280) is a human monoclonal antibody targated againts Interleukin-15 (IL-15). MW: 145.62 KD. | ||
| A2959 | Anti-IL-18 (ABT-325) | Anti-IL-18 (ABT-325) is a humanized monoclonal antibody targeted against interleukin-18 (IL-18) with the potential to treat autoimmune diseases. MW: 146.28 KD. | ||
| A2960 | Anti-IL-1b (CDP484) | Anti-IL-1b (CDP484) is an antibody targated against Interleukin-1beta (IL-1b), a cytokine that initiates inflammatory cascades. MW: 145.74 KD. | ||
| A2962 | Melrilimab (Anti-IL-1RL1 / ST2 / IL-33R) | Melrilimab (anti-IL-1RL1/ ST2 / IL-33R) is an anti-ST2 (IL-1RL) monoclonal antibody targeting the IL-33 receptor. Melrilimab has the potential to be used in asthma research. MW: 145.2 KD. | ||
| A2964 | Avizakimab (Anti-IL-21) | Avizakimab (Anti-IL-21) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets interleukin-21. MW: 145.42 KD. | ||
| A2965 | Brazikumab (Anti-IL-23) | Brazikumab (Anti-IL-23) is a human IgG2 monoclonal antibody that selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for research on Crohn's disease. MW: 144.82 KD. | ||
| A2966 | Anti-IL-23 (LY2525623) | Anti-IL-23 (LY2525623) is a human monoclonal antibody targeting Interleukin-23 (IL-23). It has the potential to be researched for autoimmune inflammatory diseases. MW: 144.26 KD. | ||
| A2967 | Mirikizumab (Anti-IL-23) | Mirikizumab (Anti-IL-23) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23. Mirikizumab can be used for research on ulcerative colitis. MW: 144.26 KD. | ||
| A2968 | Camidanlumab (Anti-IL-2Ra / CD25) | Camidanlumab (HuMax-TAC) is a human IgG1 monoclonal antibody directed against CD25 (IL-2R alpha), which is overexpressed in a variety of hematological tumors. MW: 143.98 KD. | ||
| A2972 | Anti-IL-4Ra / CD124 (MEDI2045) | Anti-IL-4Ra / CD124 (MEDI2045) is a high-affinity human and Cynomolgus cross-reactive antibody that blocks the functional interaction of IL-4 and IL-13 with their obligate receptor, IL-4Ra. MEDI 2045 has the potential to treat severe, uncontrolled asthma. MW: 143.76 KD. | ||
| A2973 | Anti-IL-5 (Abgenix anti-IL-5) | Anti-IL-5 (Abgenix anti-IL-5) is a human monoclonal antibody against interleukin-5. MW: 145.0 KD. | ||
| A2163New | Anti-mouse IL-12 p40-InVivo | |||
| A2975 | Anti-IL-6 / IFNb2 (Chugai SK2) | Anti-IL-6 / IFNb2 (Chugai SK2) is a humanized mouse monoclonal antibody that specifically binds to IL-6 and strongly inhibits IL-6 functions. MW: 145.46 KD. | ||
| A2978 | Anti-IL-6 / IFNb2 (MEDI 5117) | Anti-IL-6/IFNb2 (MEDI 5117) is a human monoclonal antibody against Interleukin-6 (IL-6), a pleiotropic cytokine with immune regulation, inflammation, and oncogenesis. It has the potential to treat rheumatoid arthritis (RA). MW: 145.14 KD. | ||
| A2980 | Sirukumab (Anti-IL-6 / IFNb2) | Sirukumab (Anti-IL-6 / IFNb2) is a humanized monoclonal IgG1κ antibody targeting IL6 (Interleukin Related). It has the potential for active lupus nephritis research. MW :144.58 KD. | ||
| A2981 | Ziltivekimab (Anti-IL-6 / IFNb2) | Ziltivekimab (Anti-IL-6 / IFNb2) is a human monoclonal antibody targeting IL-6. It has anti-inflammatory activity and may be used in studies of chronic systemic inflammation and cardiovascular disease associated with CKD. MW :145.14 KD. | ||
| A2982 | Anti-IL-6Ra / CD126 (APX007) | Anti-IL-6Ra / CD126 (APX007) is a monoclonal antibody targeting IL-6R/CD126. It can be used in the pathogenesis of multiple myeloma. MW :144.6 KD. | ||
| A2983 | Levilimab (Anti-IL-6Ra / CD126) | Levilimab (Anti-IL-6Ra / CD126) is a fully human monoclonal antibody targeting interleukin-6 receptor (IL-6R). It is an inflammation-alleviating antibody and can be used for the research of rheumatoid arthritis and covid-19 treatment. MW :145.62 KD. | ||
| A2984 | Sapelizumab (Anti-IL-6Ra / CD126) | Sapelizumab (Anti-IL-6Ra / CD126) is a human monoclonal antibody targeting IL-6. It is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. MW :144.26 KD. | ||
| A2985 | Olokizumab (Anti-IL-6 / IFNb2) | Olokizumab (Anti-IL-6 / IFNb2) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). It can be used in research of rheumatoid arthritis (RA). MW :145.4 KD. | ||
| A2138 | Anti-mouse IL-2-InVivo | Anti-mouse IL-2-InVivo reacts with mouse IL-2, a cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation. | ||
| A2797 | Anti-IL-25 | Anti-IL-25 is a humanised monoclonal antibody against Interleukin-25 (IL-25) with the potential to treat airway hyperresponsiveness (AHR). MW: 146.02 KD. | ||
| A2801 | Anti-IL-13 (CNTO 607) | Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD. | ||
| A2030 | Siltuximab (anti-IL-6) | Siltuximab (anti-IL-6) (CNTO 328) is a human-mouse chimeric monoclonal antibody that binds human interleukin-6 (IL-6). | ||
| A2032 | Brodalumab (anti-IL17RA) | Brodalumab (anti-IL17RA) (KHK4827, AMG 827) is a recombinant, fully human monoclonal antibody (IgG2) which binds with high affinity to the interleukin (IL) 17 receptor A (IL17R). | ||
| S1709 | Estradiol | Estradiol (17β-estradiol, β-Estradiol, E2, 17β-Oestradiol) is a human sex hormone and steroid, and the primary female sex hormone. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway. | ||
| S2979 | CU-T12-9 | CU-T12-9 is a specific agonist of Toll-like receptor (TLR) 1/2 with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS. | ||
| S0771 | BRD6989 | BRD6989 is a selective inhibitor of CDK8 and CDK19. BRD6989 upregulates IL-10. BRD6989 is an analog of the natural product cortistatin A (dCA). | ||
| S0094 | SR 0987 | SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer. | ||
| S2015 | Suplatast Tosylate | Suplatast Tosylate (IPD-1151T, Suplatast Tosilate) is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM. | ||
| S8133 | Resiquimod (R-848) | Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2. | ||
| S6281 | Sodium Thiocyanate | Sodium Thiocyanate (NaSCN, Sodium rhodanide, Sodium sulfocyanate, Sodium rhodanate), one of the main sources of the thiocyanate anion, is used as a precursor for the synthesis of pharmaceuticals and other specialty chemicals. Sodium thiocyanate (NaSCN) reduces IL-6, whereas increases IL-10 levels. Sodium thiocyanate also reduces ROS. | ||
| S3745 | Balsalazide disodium | Balsalazide Disodium is the disodium salt form of balsalazide, an aminosalicylate and oral prodrug that is enzymatically cleaved in the colon to produce the anti-inflammatory agent mesalazine. Balsalazide Disodium suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. | ||
| S4842 | Balsalazide | Balsalazide (Colazal, Giazo), an aminosalicylate and oral prodrug, is enzymatically cleaved in the colon to produce the anti-inflammatory agent mesalazine. Balsalazide suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. | ||
| S6579 | RCGD423 | RCGD-423 is a modulator of Glycoprotein 130 (gp130, IL6ST, IL6-beta, CD130) signalling that regulates cartilage growth and differentiation. | ||
| A2142New | Anti-mouse/rat IL-1β-InVivo | Anti-mouse/rat IL-1β-InVivo reacts with precursor and mature secreted forms of mouse and rat IL-1β a 17 kDa pro-inflammatory cytokine produced primarily by monocytes. | ||
| A2153New | Anti-mouse IL-2 (S4B6-1)-InVivo | Anti-mouse IL-2 (S4B6-1)-InVivo reacts with mouse IL-2, a 17 kDa cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation. | ||
| A2157New | Anti-mouse IL-6R-InVivo | Anti-mouse IL-6R-InVivo reacts with the mouse IL-6 receptor α chain also known as CD126. CD126 is an 80 kDa type I cytokine receptor and a member of the immunoglobulin superfamily. | ||
| A2163New | Anti-mouse IL-12 p40-InVivo |
Interleukins阻害剤の選択性比較
Tags: Interleukins inhibitor|Interleukins agonist|Interleukins activator|Interleukins inducer|Interleukins antagonist|Interleukins signaling pathway|Interleukins assay kit
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間